Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Fryinpanon Oct 31, 2021 9:52pm
153 Views
Post# 34071593

Hay Farmer

Hay FarmerHay Famer

Unless you have something intelligent and semi articulate to post, stop the nonsense.  This venue is for a written socratic discussion about Neil Cashman's science and this company's chance to make a difference.  I recommend you spend some time reading the journal articles before commenting. This endless discourse on this blog intended to hammer the leadership is tedious. ProMIS has created a series of pipelines, the envy of multi billion dollar cap companies and you can't seem relate to this fact. Sell your shares and move on. BBall seems to understand the parameters  ....you are oblivious.  Risky company, of course,  but that's the world of Neuroscience.  
<< Previous
Bullboard Posts
Next >>